Search Results - "Soerensen, Jens Benn"

Pemetrexed as first or second line in 112 danish patients by Panou, Vasiliki, Nielsen, Ida, Soerensen, Jens Benn, Roe, Oluf D.

“…Abstract only…”
Get full text

Fluorouracil Induces Myocardial Ischemia With Increases of Plasma Brain Natriuretic Peptide and Lactic Acid but Without Dysfunction of Left Ventricle by JENSEN, Søren Astrup, HASBAK, Philip, MORTENSEN, Jann, SØRENSEN, Jens Benn

“…Fluorouracil (FU) is a cornerstone of colorectal cancer treatment; however, it has clinical and subclinical influence on the heart. This study aimed to clarify…”
Get full text

5-Fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity by Jensen, Søren Astrup, Sørensen, Jens Benn

“…Aim This study aimed to elucidate the influence of 5-fluorouracil (5-FU)-based therapy on the vascular endothelium and its association with 5-FU-induced heart…”
Get full text

ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial by Vilmar, Adam, Santoni-Rugiu, Eric, Sørensen, Jens Benn

“…Abstract Aim Excision repair cross complementation group 1 (ERCC1) is a promising biomarker in advanced non-small cell lung cancer (NSCLC). However, current…”
Get full text

Prospective blinded evaluation predicting efficacy of adjuvant cisplatinum and vinorelbine by a multigene assay after radical surgery in non-small cell lung cancer by Buhl, Ida Kappel, Santoni-Rugiu, Eric, Ravn, Jesper, Hansen, Anker, Christensen, Ib Jarle, Jensen, Thomas, Jensen, Peter Buhl, Askaa, Jon, Knudsen, Steen, Soerensen, Jens Benn

“…Abstract only…”
Get full text

Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel by De Marinis, Filippo, Eberhardt, Wilfried, Harper, Peter G, Sureda, Bartomeu Massuti, Nackaerts, Kristiaan, Soerensen, Jens Benn, Syrigos, Kostas, Trédaniel, Jean

“…Bisphosphonates (BPs) are effective in preventing, reducing the incidence, and delaying the onset of skeletal-related events in patients with bone metastases…”
Get more information

Mature overall survival (OS) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM) by Nowak, Anna K., Grosso, Federica, Steele, Nicola, Novello, Silvia, Popat, Sanjay, Greillier, Laurent, John, Tom, Leighl, Natasha B., Reck, Martin, Pavlakis, Nick, Soerensen, Jens Benn, Planchard, David, Ceresoli, Giovanni Luca, Hughes, Brett Gordon Maxwell, Mazieres, Julien, Socinski, Mark A., Velema, Derek, von Wangenheim, Ute, Morsli, Nassim, Scagliotti, Giorgio V.

“…Abstract only 8506 Background: LUME-Meso is a Phase (Ph) II/III, double-blind, randomized study. N targets MPM by inhibiting VEGFR 1–3, PDGFR α/β, FGFR 1–3,…”
Get full text

Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report by Rossing, Henrik H, Grauslund, Morten, Urbanska, Edyta M, Melchior, Linea C, Rask, Charlotte K, Costa, Junia C, Skov, Birgit G, Sørensen, Jens Benn, Santoni-Rugiu, Eric

“…Anaplastic lymphoma kinase-positive non-small cell lung carcinoma patients are generally highly responsive to the dual anaplastic lymphoma kinase and MET…”
Get full text

Diagnosis of malignant pleural mesothelioma by Sørensen, Jens Benn

Get more information